AACR Q&A: Elaine Mardis

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.

By The Scientist Staff | April 18, 2016


The American Association for Cancer Research (AACR) annual meeting is huge—so big that it can be tough to choose which talks to attend in person (or tune in to from afar). The Scientist asked Washington University in St. Louis’s Elaine Mardis—who is on the planning committee for this year’s conference, being held in New Orleans—to share her picks of the most buzzworthy topics in cancer research today.

The Scientist: To your mind, what are some of the hottest areas of cancer research right now?

Elaine Mardis: Immunotherapy and immunogenomics, liquid biopsy-based monitoring of patient response to therapy, [and] clinical genomic assays to identify therapeutic targets.

TS:  What are you presenting at AACR this year?  

EM: I am speaking in the opening plenary about cancer genomics and its transition to aid patient care in the cancer clinic. I also am providing a wrap-up of the cancer prevention and early detection work [being] presented at the meeting this year.                

TS: What new topics are emerging that have received less attention in past conferences?

EM: Liquid biopsy and early detection of cancers. Germline contribution of cancer susceptibility mutations in patients without a family history of cancer.

TS: What talks or posters do you anticipate finding most exciting?

EM: I think the Wednesday plenary lectures on single-cell genomics and the tumor heterogeneity plenary on Tuesday will have the most exciting talks.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Dartmouth Professor Investigated for Sexual Misconduct Retires
  2. Two University of Rochester Professors Resign in Protest
  3. Theranos Leaders Indicted For Fraud
    The Nutshell Theranos Leaders Indicted For Fraud

    Federal prosecutors filed criminal charges that allege the company’s promise to revolutionize blood testing swindled investors out of hundreds of millions of dollars and put patients in danger.

  4. Laxative Causes Long-Term Changes to Mouse Microbiome